Evolutionary Genomics (Evolutionary Genomics) Growth Rank : 0 (As of Jun. 22, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics Growth Rank?

Evolutionary Genomics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Evolutionary Genomics Growth Rank Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolutionary Genomics (Evolutionary Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

4220 Morning Star Drive, Castle Rock, CO, USA, 80108

Website

https://www.evolgen.com

Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.

Executives

Steve B Warnecke	director, 10 percent owner, officer: Chairman, CEO	C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff	director	4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier	officer: Secretary / Treasurer	1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess	director	7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz	director, 10 percent owner	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess	director, 10 percent owner, officer: President/CEO	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita	director, officer: Secretary/Treasurer/CFO	5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics (Evolutionary Genomics) Headlines

No Headlines